“AIIMS, New Delhi is the site for COVAXIN Phase III clinical trials, which is an all-virus inactivated vaccine co-sponsored by the Indian Medical Research Council (ICMR) and Barrat Biotech,” AIIMS said in an ad.
Dr. Sanjay K Rai of the AIIMS Community Medicine Center has announced through an advertisement that Phase I / II trials (safety and immunogenicity) have already been completed.
AIIMS also notified that anyone interested in the exam could contact the hospital administrator by phone number +917428847499 or email firstname.lastname@example.org.
The final day of admission is December 31, 2020.
Earlier, on December 19, Federal Health Minister Hirschwaldan said national scientists and health experts were working on the development of indigenous vaccines, and India would inoculate about 3 billion rupees in the next 6-7 months. He said he has the ability to.
According to the Ministry of Health, six vaccine candidates at various stages of clinical trials are Covishield, Covaxin, ZyCoV-D, Sputnik V, NVX-CoV2373, and recombinant protein antigen-based vaccines.
In addition to the above six in various trial stages, the following three are in preclinical trial stages-HGCO 19, Inactivated Rabies Vector Platform and VesculoVax Platform.